ENTREMED, INC. (NASDAQ:ENMD)
CAPS Rating:
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
Recs
Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m